Anti-hIL-12/IL-23-p40-hIgG1
-
Cat.code:
hil12p40-mab1
- Documents
ABOUT
Anti-human IL-12/IL-23 - Ustekinumab biosimilar - CAS #815610-63-0
Anti-hIL-12/IL-23-p40-hIgG1 is a biosimilar antibody of Ustekinumab targeting the shared p40 subunit of interleukins IL-12 and IL-23. Ustekinumab inhibits the activity of IL-12 and IL-23 by preventing their binding to the IL-12 receptor β1 (L-12Rβ1). Ustekinumab is FDA-approved for treating autoimmune disorders such as Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Anti-hIL-12/IL-23-p40-hIgG1 comprises the variable region of Ustekinumab and the IgG1 constant region of Ustekinumab for high effector functions.
This antibody can be used together with recombinant human IL-12 for screening and neutralization assays to block IL-12 signaling in HEK-Blue™ IL-12 cells. It can also be used together with recombinant human IL-23 for screening and neutralization assays to block IL-23 signaling in HEK-Blue™ IL-23 cells (see figures).
Key features
- Each lot is functionally tested and validated
- The complete sequence of the antibody construct has been verified
- Absence of endotoxins determined by the EndotoxDetect assay
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
IL-12, IL-23
Human
Neutralization assay, ELISA
Sodium phosphate buffer, glycine, saccharose, stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Neutralization assay, ELISA
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hIL-12/IL-23-p40-hIgG1
-
Cat code:hil12p40-mab1
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20 °C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Ustekinumab background
Ustekinumab is a fully human IgG1 monoclonal antibody (mAb) targeting the shared p40 subunit of interleukin 12 (IL-12) and IL-23 [1]. These cytokines are critical in driving inflammatory and autoimmune responses associated with various diseases [1-2]. By binding to the p40 subunit, Ustekinumab blocks the interaction of IL-12 and IL-23 with the IL-12 receptor β1 (IL-12Rβ1 or CD212) found on the surface of natural killer cells and T cells [1]. Importantly, Ustekinumab does not bind to endogenous IL-12 or IL-23 already complexed with the receptor, making it unlikely to mediate Fc effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) [1].
Upon binding, Ustekinumab neutralizes IL-12-mediated responses, including STAT4 phosphorylation, cell surface marker expression, and IFNγ cytokine production. Similarly, it inhibits IL-23-driven responses, such as STAT3 phosphorylation and the production of cytokines IL-17A, IL-17F, and IL-22 [1]. By blocking these pathways, Ustekinumab suppresses the activation and differentiation of CD4+ T cells and inhibits Th1 and Th17 signaling cascades, leading to a significant reduction in inflammation [1-2]. These mechanisms underlie its clinical efficacy in treating several immune-mediated disorders. Ustekinumab is FDA-approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis [3].
References:
1. Benson, J.M, et al., 2011. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 3(6):535-545.
2. Montepaone M, et al. 2014. Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis. Open Access Rheumatol. ;6:7-13.
3. FDA website accessed in Nov 2024: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761044s013lbl.pdf#page=37
DOCUMENTS
Documents
Validation Data Sheet
Technical Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
